Trial of New Alzheimer’s Drug Reports Disappointing Results
The drug, crenezumab, failed to prevent early symptoms or slow cognitive decline, the latest setback in the long quest to find effective therapies for the disease.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.